State Street SPDR S&P Biotech ETF (XBI)
| Assets | $8.81B |
| Expense Ratio | 0.35% |
| PE Ratio | n/a |
| Shares Out | 63.88M |
| Dividend (ttm) | $0.44 |
| Dividend Yield | 0.34% |
| Ex-Dividend Date | Dec 22, 2025 |
| Payout Ratio | n/a |
| 1-Year Return | +63.65% |
| Volume | 7,634,628 |
| Open | 132.23 |
| Previous Close | 133.04 |
| Day's Range | 131.07 - 134.44 |
| 52-Week Low | 75.68 |
| 52-Week High | 139.19 |
| Beta | 0.88 |
| Holdings | 156 |
| Inception Date | Jan 31, 2006 |
About XBI
Fund Home PageThe State Street SPDR S&P Biotech ETF (XBI) is an exchange-traded fund that is based on the S&P Biotechnology Select Industry index. The fund tracks an equal-weighted index of US biotechnology stocks. XBI was launched on Jan 31, 2006 and is issued by State Street.
Top 10 Holdings
14.40% of assets| Name | Symbol | Weight |
|---|---|---|
| Apellis Pharmaceuticals, Inc. | APLS | 1.80% |
| Travere Therapeutics, Inc. | TVTX | 1.50% |
| Revolution Medicines, Inc. | RVMD | 1.49% |
| TG Therapeutics, Inc. | TGTX | 1.44% |
| Twist Bioscience Corporation | TWST | 1.43% |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1.40% |
| Summit Therapeutics Inc. | SMMT | 1.39% |
| Erasca, Inc. | ERAS | 1.32% |
| Alkermes plc | ALKS | 1.32% |
| Madrigal Pharmaceuticals, Inc. | MDGL | 1.31% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 22, 2025 | $0.40656 | Dec 24, 2025 |
| Sep 22, 2025 | $0.02665 | Sep 24, 2025 |
| Jun 23, 2025 | $0.0073 | Jun 25, 2025 |
| Mar 24, 2025 | $0.00525 | Mar 26, 2025 |
| Dec 23, 2024 | $0.00269 | Dec 26, 2024 |
| Sep 23, 2024 | $0.01523 | Sep 25, 2024 |
News
Funding for Risky Biotechs Is Returning
Publicly traded drug developers sold more than $13 billion of shares in the fourth quarter, the most in more than four years.
Mizuho's Jared Holz on what biotech dealmaking looks like in 2026
Jared Holz, Mizuho health care equity strategist, joins 'The Exchange' to discuss the surge in pharma M&A in 2025, ACA subsidies expiring, and more.
Why 2026 may be a strong year for biotech stocks
Biotech stocks have staged an impressive rally over the past six months, with the XBI index – key benchmark for small and mid-cap biotech names – posting one of its strongest stretches on record. Mizu...
Mizuho's Jared Holz on why he is bullish on biotech heading into 2026
Jared Holz, Mizuho, joins 'Power Lunch' to talk how to play healthcare and biotech moving into 2026.
Novo Nordisk's Wegovy Pill Shakes Up Rivalry With Eli Lilly, Puts Health Care ETFs In Focus
The approval of Novo Nordisk's (NYSE: NVO)oral Wegovy is bringing new interest to health care and pharmaceutical ETFs that provide access to the growing GLP-1 market without requiring investors to cho...
Final Trades: Toast, Uber, the XLB and the XBI
The Investment Committee reveals the stocks they're watching as the market sets up for its next move.
The Fed cut rates. Biotech didn't notice.
Biotechs are instead spending their time advancing the kind of smart science that will catch the eye of cash-rich pharmaceutical companies.
Final Trades: FTAI, ETN, COWZ, XBI
The Investment Committee give you their top stocks to watch for the second half.
Final Trades: Taiwan Semi, Apple and the XBI
The Investment Committee give you their top stocks to watch for the second half.
If M&A continues at this pace you want to be long Biotech into next year, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk the uptick in biotech and pharma M&A, what it is signaling, and how to play it.
Final Trades: Taiwan Semi, HealthEquity, CBOE Global Markets and the XBI
The Investment Committee give you their top stocks to watch for the second half.
Biotech is back and a constructive place to put money to work, says Piper Sandler's Craig Johnson
Craig Johnson, Piper Sandler chief market technician, joins 'The Exchange' to discuss the market technicals, if its a real market rotation and much more.
Top 6 ETFs To Watch As Wall Street's Strongest Six Months Begin
Right now ahead of Halloween, the real suspense might be in ETF investing strategies. With markets seesawing between hopes for rate cuts and the resilience of earnings, investors are dusting off one o...
Biotech Stocks Have Struggled Since 2021. Why They're Coming Back.
Too many questionable start-ups went public during the pandemic, when the sector was hot. Now, after over four years of pain, the weak have failed, rates are falling, and M&A looks to be on the upswin...
RTW Investments' Rod Wong: Expect more deals in biotech space
Rod Wong, RTW Investments CIO & Managing Director, joins CNBC's 'Money Movers' to discuss J&J's reported interest in buying Protagonist Therapeutics, whether he expects more consolidation in the secto...
Trade Tracker: Joe Terranova buys more XBI
Joe Terranova, senior managing director at Virtus Investment Partners, joins CNBC's "Halftime Report" to explain why he's buying XBI again. The committee share their health care strategy.
How to trade the health care break out
The health care sector up 6.5% in one week. The Investment Committee debate how to trade the space.
Final Trades: SoFi Technologies, Clearway Energy, SPDR S&P Biotech ETF and CrowdStrike
The Investment Committee's top stock picks are in—here's what they're watching now.
Biotech Sector Shows No Signs of Slowing. 3 Stocks That Make the Grade.
Last week, the SPDR S&P Biotech ETF surged 6%.
Trump's Biotech Playbook Ignites $350 Billion Investment Blitz
Biotech is back – and it's playing for keeps. President Donald Trump's second-term policies have unleashed a staggering ~$350 billion surge in U.S.-based pharmaceutical and biotech investments, from d...
Real assets in biotech serving big markets the Street is finally noticing, says Mizuho's Jared Holz
Jared Holz, Mizuho healthcare strategist, joins 'Power Lunch' to discuss the change in sentiment in the healthcare sector, the differences in the biotech ETFs and much more.
Healthcare industry can handle and absorb tariffs, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Power Lunch' to discuss what tariffs mean for the pharma industry, what could be a blockbuster for Eli Lilly and much more.